-
Anti-Inflammatory Therapies Learn more ›
- Not Applicable
- Phase One
- Phase Two
- Phase Three
- Phase Four
- To Patients
-
Alpha-Synuclein Targeting Therapies Learn more ›
- Not Applicable
- Phase One
- Phase Two
- Phase Three
- Phase Four
- To Patients
- Affitope(R) PD01A › : To Patients ›
- Sirolimus› : To Patients ›
- FTY 720 (Fingolimod)› : To Patients ›
- Belnacasan (VX-765)› : To Patients ›
- SynuClean-D› : To Patients ›
- Kallikrein-6› : To Patients ›
- MPLA› : To Patients ›
- BIIB101› : To Patients ›
- Lu AF82422 (alpha-synuclein mAb)› : To Patients ›
- ATH434 (formerly, PBT434 -Alterity Therapeutics)› : To Patients ›
- NBMI› : To Patients ›
- TAK-341› : To Patients ›
-
Neuroprotective Therapies Learn more ›
- Not Applicable
- Phase One
- Phase Two
- Phase Three
- Phase Four
- To Patients
- Intranasal insulin (INI) › : To Patients ›
- Stearoyl-CoA desaturase inhibition› : To Patients ›
- Verdiperstat (BHV-3241) › : To Patients ›
- BNN-20 › : To Patients ›
- Exenatide› : To Patients ›
- Gene therapy (AAV2-GDNF)› : To Patients ›
- Inosine 5-monophosphate› : To Patients ›
- Ubiquinol› : To Patients ›
- Stem cells› : To Patients ›
-
Diagnosis & Biomarkers Learn more ›
- Not Applicable
- Phase One
- Phase Two
- Phase Three
- Phase Four
- To Patients
- Alpha-synuclein› : To Patients ›
- Neuroimaging› : To Patients ›
- Alzheimer’s disease biomarkers› : To Patients ›
- Natural history study› : To Patients ›
- Brain network activation› : To Patients ›
- [18F]F-DOPA imaging› : To Patients ›
- Digital speech analysis (Voice4PD-MSA)› : To Patients ›
- Gait analysis› : To Patients ›
- Magnetic resonance imaging (MRI)› : To Patients ›
- Brain scans› : To Patients ›
- DaTSCAN™ Ioflupane (123l) injection/SPECT imaging› : To Patients ›
- MorphomerTM library PET tracer specific for alpha synuclein› : To Patients ›
- Transcranial magnetic stimulation (TMS)› : To Patients ›
- Web-based automated imaging (MRI)› : To Patients ›
-
Symptomatic Treatments Learn more ›
- Not Applicable
- Phase One
- Phase Two
- Phase Three
- Phase Four
- To Patients
- Ampreloxetine/TD-9855› : To Patients ›
- Atomoxetine› : To Patients ›
- Swallowing therapy› : To Patients ›
- Expiratory muscle strength training (EMST)› : To Patients ›
- Zoledronic acid › : To Patients ›
- NDMA modulator › : To Patients ›
- Safinamide› : To Patients ›
- Botulinum A toxin› : To Patients ›
- Riluzole› : To Patients ›
- Fipamezole (JP-1730)› : To Patients ›
- Droxidopa› : To Patients ›
- Midodrine and droxidopa› : To Patients ›
- Nebivolol› : To Patients ›
- Midodrine› : To Patients ›
- Deep brain stimulation (DBS) and spinal cord stimulation (SCS)› : To Patients ›
- Transcranial direct current stimulation (tDCS)› : To Patients ›
- Abdominal binder› : To Patients ›
- Continuous positive airway pressure (CPAP) › : To Patients ›
- Brain computer interface› : To Patients ›
- Spinal cord stimulation (SCS)› : To Patients ›
- Deep brain stimulation (DBS)› : To Patients ›
- Repetitive transcranial magnetic stimulation (rTMS) and physical therapy› : To Patients ›
- Transcranial magnetic stimulation (TMS)› : To Patients ›